Testosterone replacement therapy for late-onset hypogonadism

Nature Clinical Practice Urology

Volumn 3, Issue 5, 2006, Pages 260-267

  Cunningham, Glenn R ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Aging; Male hypogonadism; Testosterone deficiency; Testosterone replacement therapy

Indexed keywords

ANDROSTANOLONE; ESTROGEN; GESTAGEN; GLUCOCORTICOID; GONADORELIN AGONIST; KETOCONAZOLE; OPIATE DERIVATIVE; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE BINDING GLOBULIN; SPIRONOLACTONE; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

AGING; APPLICATION SITE REACTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DATA ANALYSIS; DEVELOPED COUNTRY; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ERYTHROCYTOSIS; GINGIVA DISEASE; GROUPS BY AGE; HORMONE DEFICIENCY; HORMONE RESPONSE; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; INJECTION PAIN; LONGITUDINAL STUDY; MENOPAUSAL SYNDROME; PATIENT MONITORING; PERSONALITY DISORDER; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SKIN IRRITATION; SLEEP APNEA SYNDROME; SUPPLEMENTATION; SYMPTOMATOLOGY; TESTOSTERONE BLOOD LEVEL; THROMBOEMBOLISM;

AGE FACTORS; ANDROGENS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; TESTOSTERONE;

EID: 33646687268     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro0479     Document Type: Review

References (28)

1. Hijazi RA and Cunningham GR (2005) Andropause: Is androgen replacement therapy indicated for the aging male? Annu Rev Med 56: 117-137
2. Nieschlag E et al. (2004) Testosterone replacement therapy: Current trends and future directions. Hum Reprod Update 10: 409-419
3. Handelsman DJ and Liu PY (2005) Andropause: Invention, prevention, rejuvenation. Trends Endocrinol Metab 16: 39-45
4. Kaufman JM and Vermeulen A (2005) The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26: 833-876
5. Cunningham GR et al. (2001) Summary from the Second Annual Andropause Consensus Meeting, Los Angeles, CA, 2001. Bethesda, MD: The Endocrine Society
6. American Association of Clinical Endocrinologists Hypogonadism Task Force (2002) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocr Pract 8: 440-456
7. Nieschlag E et al. (2005) Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol 48: 1-4
8. Steidle C et al. (2003) AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 88: 2673-2681
9. Grady D et al. (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288: 49-57
10. Anderson GL et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712
11. Manson JE et al. (2003) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349: 523-534
12. Espeland MA et al. (2004) Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study JAMA 291: 2959-2968
13. Shumaker SA et al. (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291: 2959-2968
14. Matsumoto AM and Bremner WJ (2004) Serum testosterone assays - accuracy matters. J Clin Endocrinol Metab 89: 520-524
15. Meikle AW et al. (1992) Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 74: 623-628
16. Swerdloff RS et al. (2000) Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. Clin Endocrinol Metab 85: 4500-4510
17. Snyder PJ and Lawrence DA (1980) Treatment of male hypogonadism with testosterone enanthate J Clin Endocrinol Metab 51: 1335-1339
18. von Eckardstein S and Nieschlag E (2002) Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: A phase II study. J Androl 23: 419-425
19. Wang C et al. (2004) New testosterone buccal system (Striant) delivers physiological testosterone levels: Pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab 89: 3821-3829
20. Rosen J and Negro-Vilar A (2002) Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile. J Musculoskelet Neuronal Interact 2: 222-224
21. Gray PB et al. (2005) Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab 90: 3838-3846
22. Liverman CT and Blazer DG (2004) Testosterone and Aging. Washington DC: The National Academies Press
23. Snyder PJ (2004) Hypogonadism in elderly men - what to do until the evidence comes. N Engl J Med 350: 440-442
24. Jemal J et al. (2005) Cancer Statistics, 2005. CA Cancer J Clin 55: 10-30
25. Johns LE and Houlston RS (2003) A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 91: 789-794
26. Thompson IM et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per millilitre. N Engl J Med 350: 2239-2246
27. Bhasin S et al. (2003) Managing the risks of prostate disease during testosterone replacement therapy in older men: Recommendations for a standardized monitoring plan. J Androl 24: 299-311
28. Rhoden EL and Morgentaler A (2004) Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 350: 482-492